| Status: Medicine does not meet criteria for AWMSG assessment | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA1011: Belzutifan for treating tumours associated with von Hippel-Lindau disease |
|
Medicine details |
|
| Medicine name | belzutifan (Welireg®) |
| Formulation | intravenous infusion |
| Reference number | 4991 |
| Indication | Treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for VHL associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumours (pNET), and for whom localised procedures are unsuitable or undesirable |
| Company | Merck Sharp & Dohme Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 17/03/2023 |
| NICE guidance | TA1011: Belzutifan for treating tumours associated with von Hippel-Lindau disease |